Drug Trial Radar · NCT02193074
A Study to Assess the Efficacy and Safety of Nusinersen (ISIS 396443) in Infants With Spinal Muscular Atrophy
Last checked: Nov 20, 2026Latest source record: Feb 17, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
122
Actual
Start
Aug 19, 2014
Primary completion
Nov 21, 2016
Study completion Nov 21, 2016
Sponsor
- Lead sponsor
- BiogenBiogen (BIIB)
- Sponsor type
- Industry
- First posted
- Jul 17, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, up to 210 days
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the study is to examine the clinical efficacy of nusinersen (ISIS 396443) administered intrathecally (IT) to participants with infantile-onset with infantile-onset spinal muscular atrophy (SMA). The secondary objective of the study is to examine the safety and tolerability of nusinersen administered intrathecally to participants with infantile-onset SMA.
Conditions
- Spinal Muscular Atrophy
Interventions
nusinersenDrug
Administered by intrathecal (IT) injection as specified in the treatment arm.
Sham procedureProcedure
Small needle prick on the lower back at the location where the IT injection is normally made
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Motor Milestones RespondersTime frame: assessed at the later of the Day 183, Day 302, or Day 394 study visits
- Time to Death or Permanent VentilationTime frame: Day 91, Day 182, Day 273, Day 364, Day 394
Locations
31 sites in 13 countries. Site status is shown where the registry gives one.
UCLA Medical Center
Los Angeles, California
Children's Hospital Colorado
Aurora, Colorado
Nemours Children's Hospital
Orlando, Florida
Ann and Robert H. Lurie Children's Hospital of Chicago
Chicago, Illinois
Boston Children's Hospital
Boston, Massachusetts
Washington University School of Medicine
St Louis, Missouri
Columbia University Medical Center
New York, New York
Duke Children's Hospital
Durham, North Carolina
Doernbecher Children's Hospital
Portland, Oregon
Children's Hospital of Philadelphia - Neurology
Philadelphia, Pennsylvania
UT Southwestern Medical Center/Children's Medical Center Dallas
Dallas, Texas
Primary Children's Medical Center (University of Utah)
Salt Lake City, Utah
Sydney Children's Hospital
Sydney, New South Wales, Australia
Royal Children's Hospital, Children's Neuroscience Centre
Parkville, Victoria, Australia
Hôpital Universitaire des Enfants Reine FABIOLA (HUDERF)
Brussels, Belgium
British Columbia Children's Hospital/UBC
Vancouver, British Columbia, Canada
Hospital for Sick Children
Toronto, Ontario, Canada
Institut de Myologie
Paris, France
Universitatsklinikum Essen
Essen, Germany
Universtatsklinikum Freiburg, Zentrum fur Kinder-und Jugendmedizin , Abteilung Neuropadiatrie und Muskelerkrankungen
Freiburg im Breisgau, Germany
Istituto Giannina Gaslini, Centro Traslazionale di Miologia e Patologie Neurodegenerative
Genova, Italy
Pediatric Neurology Unit, Catholic University
Rome, Italy
Tokyo Women's Medical University
Tokyo, Japan
Hyogo College of Medicine
Nishinomiya, Hyōgo, Japan
Seoul National University Hospital
Seoul, South Korea
Hospital Universitario Vall d'Hebron
Barcelona, Spain
Hospital Universitario La Paz, Pediatric Neurology Department
Madrid, Spain
University of Gothenburg, The Queen Silvia Children's Hospital
Gothenburg, Sweden
Hacettepe Children's Hospital
Ankara, Turkey (Türkiye)
UCL Institute of Child Health/Great Ormond Street
London, United Kingdom
MRC Centre for Neuromuscular Diseases at Newcastle, Institute of Genetic Medicine Newcastle University
Newcastle, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.